Last reviewed · How we verify

NCT06217224: PBMT/MTX

Evaluation of Prophylactic Photobiomodulation Therapy in Patients With Osteosarcoma

Status unknown NA Last updated 22 January 2024
What this trial tests

NA trial testing Preventive photobiomodulation Therapy (PBMT) in Mucositis Oral in 53 participants. Status unknown.

Timeline
17 October 2022
Primary endpoint
30 June 2025
30 July 2025

Quick facts

Lead sponsorInstituto Nacional de Cancer, Brazil
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment53
Start date17 October 2022
Primary completion30 June 2025
Estimated completion30 July 2025
Sites1 location across Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Instituto Nacional de Cancer, Brazil — full company profile →

Who can join

Under 19, any sex, with Mucositis Oral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the photobiomodulation therapy (PBMT) for the prevention of oral mucositis in osteosarcoma patients submitted to high doses of methotrexate, through two different protocols. As a hypothesis, photobiomodulation for the prevention of oral mucositis after cycles of Cisplatin, Doxorubicin and Methotrexate is more effective than just the application of preventive low-power laser after Methotrexate alone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Instituto Nacional de Cancer, Brazil trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06217224.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing